Top Markets
#1 Nesa Nesa +808.96%
#2 Cortex Cortex +68.17%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.37%
#4 QuantixAI QuantixAI +23.90%
#5 EXOD EXOD +22.78%
#6 BSquared Network BSquared Network +18.87%
#7 Instadapp Instadapp +16.15%
#8 Pons Pons +15.93%
#9 Magma Finance Magma Finance +13.38%
#10 PondCoin PondCoin +13.28%
Coin of the day
Nesa Nesa
設定
言語
日本
通貨
USD
テーマ
Hangzhou Tigermed Consulting Co., Ltd Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting Co., Ltd

300347
株式のランク #3418
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
株価
$7.37
時価総額
$5.44B
変化（1日）
-2.70%
変化（1年）
-19.39%
国
CN
取引 Hangzhou Tigermed Consulting Co., Ltd (300347)

カテゴリー

Healthcare
Hangzhou Tigermed Consulting Co., Ltd（300347）のP/E比率
2026 時点のP/E比率 TTM 0
Hangzhou Tigermed Consulting Co., Ltd の最新の財務報告および株価によると、現在の P/E (TTM) は 0 です。2026 年末時点での P/E は 0 でした。
Hangzhou Tigermed Consulting Co., Ltd の P/E 比率の履歴（2026 〜 2026）
各年末のP/E比率
年 P/E比率 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
P/E比率の読み方

株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。